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Presentation Overview 
Review of mammalian immunity 
Progression of models 
o Nudes 
o scid mutants 
o Rag1 knockouts 
o NOD scid gamma (NSG) 
Applications in human disease research  
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Development of Immunodeficient Mice 
The ongoing search for the perfect host 
Shultz LD et al. 2007. Nat Rev Immunol  7(2):118-30. PMID:17259968 
3 JAX® Mice   |   
www.jax.org/jaxmice/cancer/xenoHosts 
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Immune System Components 
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Inbred and Outbred Nude Mice 
Mouse Nomenclature 
Inbred Nude NU/J (002019) 
Outbred Nude J:NU (007850) 
Immunological Deficiencies 
Mutation:  Foxn1nu 
Athymic and T cell Deficient 
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Flanagan SP. 1966. Genet Res 8(3):295-309. PMID:5980117 
Pantelouris EM. 1973. Differentiation 1(6):437-50. PMID:4547146 
Inbred and Outbred Nude Mice 
Applications and Benefits 
Engraftment of human & mouse 
tumor cell lines 
Well published/characterized 
Hairless phenotype enhances 
assessment of tumor growth 
Flanagan SP. 1966. Genet Res 8(3):295-309. PMID:5980117 
Pantelouris EM. 1973. Differentiation 1(6):437-50. PMID:4547146 
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Immune System Components 
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Before treatment After treatment 
Easy Evaluation of Therapeutic 
Response in Nude Mice 
 
Gulliya KS et al. 1994. Cancer 74(6):1725-32. PMID:8082074 
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Nude Mice 
Considerations 
Innate immunity intact 
Not useful for hematopoietic 
cancer models 
Not suitable for primary cell 
transplantation 
Flanagan SP. 1966. Genet Res 8(3):295-309. PMID:5980117 
Pantelouris EM. 1973. Differentiation 1(6):437-50. PMID:4547146 
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BALB/c-scid 
Mouse Nomenclature 
 CBySmn.CB17-Prkdcscid/J  
(001803) 
o Similar to original C.B-17 scid 
Immunological Deficiencies 
 Mutation: scid “severe combined 
immune deficiency” 
 No mature B and T cells 
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BALB/c-scid 
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Applications 
 Xenograft host for cancer cell lines 
 Efficacy testing of therapeutic 
antibodies (CDC and ADCC intact) 
 Adoptive transfer from BALB/c 
donors 
 Infectious disease 
 Compound immunodeficient 
mutants 
Immune System Components 
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BALB/c-scid mice are an Effective Model for 
Testing Therapeutic Ab Efficacy in Tumor 
Growth and Metastasis 
Zhang D et al. 2010. Cancer Res 70:2495-2503. PMID:20197464 
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BALB/c-scid Mice Used for Evaluating Therapeutic 
Ab Efficacy on Tumor Growth and Vascularity 
Shin S et al. 2011. Mol Cancer Ther 10:603-614. PMID:21393427 
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BALB/c-scid Mice Used for Evaluating Therapeutic 
Ab Efficacy on Tumor Growth and Vascularity 
Shin S et al. 2011. Mol Cancer Ther 10:603-614. PMID:21393427 
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Considerations 
Innate immunity intact 
scid side effects: radiation 
sensitivity; genotoxic drugs may 
have 
    higher toxicity 
High scid leakiness; mice 
develop T and B cells as they 
age 
BALB/c-scid 
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B6 Rag1 KO 
Mouse Nomenclature 
B6.129S7-Rag1tm1Mom/J (002216) 
Immunological Deficiencies 
Mutation:  Rag1 Knockout 
No mature B and T cells 
Mombaerts P et al. 1992. Cell 65(5):869-77.  PMID: 1547488 
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B6 Rag1 KO 
Applications and Benefits 
Xenograft host, but mostly an 
immunology tool 
Efficacy testing of therapeutic 
antibodies 
Adoptive transfer from C57BL/6 
donors 
Radiation resistant 
Common inbred background 
simplifies creation of compound 
immunodeficient mutants 
Mombaerts P et al. 1992. Cell 65(5):869-77.  PMID: 1547488 
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Immune System Components 
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Adoptive Transfer of Tregs in B6 
Rag1 KO Mice 
Trandem K. 2010. J Immun 184(8):4391-40. PMID:20208000 
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B6 Rag1 KO 
Considerations 
Functional innate immunity 
(normal natural killer cell 
function) 
Poor host for primary human 
cells 
Mombaerts P et al. 1992. Cell 65(5):869-77. PMID:1547488 
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NOD-scid 
Mouse Nomenclature 
NOD.CB17-Prkdcscid/J (001303) 
Immunological Deficiencies 
Mutation: scid “severe 
combined immune deficiency” 
No mature B and T cells 
Reduced innate immunity 
o macrophage, dendritic, and NK cell 
deficits 
o complement deficient 
Shultz LD et al. 1995. J Immunol 154(1):180-91.PMID:7995938 
Banuelos SJ et al. 2004. Clin Immunol 112(3):273-83. PMID:15308121 
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NOD-scid 
Applications 
Xenotransplantation of human 
tumors 
Engrafts some hematopoietic 
cancer cell lines 
Adoptive transfer recipient for 
study of autoimmune type 1 
diabetes 
Significantly less scid leakiness 
than other backgrounds 
Shultz LD et al. 1995. J Immunol 154(1):180-91.PMID:7995938 
Banuelos SJ et al. 2004. Clin Immunol 112(3):273-83. PMID:15308121 
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Immune System Components 
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Immune System Components 
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NOD-scid Mice Propagate 
Medulloblastoma-like Tumors 
Werbowetski-Ogilvie TE  et al. 2012. Stem Cells 30(3):392-404 PMID:22213600 
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NOD-scid 
Considerations 
Short life span (thymic 
lymphoma by ~9 months 
Residual innate immunity (NK 
cell function) 
scid side effects: radiation 
sensitivity; genotoxic drugs 
may have higher toxicity 
Shultz LD et al. 1995. J Immunol 154(1):180-91. PMID:7995938 
Banuelos SJ et al. 2004. Clin Immunol 112(3):273-83. PMID:15308121 
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NSG, NOD scid gamma 
Mouse Nomenclature 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ 
(005557) 
Immunological Deficiencies 
 NOD background: innate immune 
deficiencies 
o Absence of hemolytic complement 
o Reduced dendritic cell function 
o Defective macrophages 
 scid mutation: T and B cell 
deficiency 
 Il2rg : NK cell deficiency 
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NSG, NOD scid gamma 
Benefits 
No scid-associated leakiness 
Longer life span than NOD-
scid (> 16 months)  
Enhanced human 
hematopoietic stem cell 
engraftment (Sirpa allele) 
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Immune System Components 
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NSG, NOD scid gamma 
Considerations 
scid side effects:  
o radiation sensitivity  
o genotoxic drugs may have higher 
toxicity 
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NSG Applications 
The most useful and versatile 
immunodeficient mouse model 
To find NSG information online, visit  
www.jax.org/jaxmice/research/immunology/005557 
Research applications 
Primary tumor engraftment 
Hematological cancers 
Human hematopoiesis  
Infectious disease 
Cell replacement therapy for type 1 diabetes 
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NSG mice preserve patient tumor 
characteristics: ER+ Breast Carcinoma 
NSG supports growth of ER+ breast tumors in combination with estrogen pellets 
Tumors retain “organoid” growth pattern 
TM00386 PT TM00386-294 P0 
PT= Patient Tumor; P0 = first patient derived xenograft (PDX) generation in mouse; 
P1 = 2nd generation   
TM00386-294 P1 
 TM00386 (ER+/PR+/Her2-) 
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TM00134-PT TM00134-216P0 TM00134-216P1 
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TM00388-P0 TM00388-PT 
Colon Adenocarcinoma Metastatic to Lung 
Colon Adenocarcinoma, KRAS G13D 
NSG mice preserve patient tumor 
characteristics: ER+ Breast Carcinoma 
NSG Mice 
Effective Host for Primary AML Cells 
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Human Hematopoiesis in NSG Mice 
Most efficient engraftment of human HSCs to date 
Permits differentiation of all major cell types: 
o Myeloid lineage 
Erythrocytes, megakaryocytes 
Monocytes, macrophages, dendritic cells, granulocytes, NK cells 
o Lymphoid lineage 
T cells (CD4+ and CD8+) 
B cells 
Some mucosal and adaptive immune functions 
Ishikawa F et al. 2005. Blood 106(5):1565-73. PMID:15920010 
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Experimental Timeline for JAX® Hu-NSG 
 
Human   
T cells 
appear 
Human   
B cells 
appear 
Whole body irradiation 
Tail vein injection 
3 weeks 12 weeks 15 weeks Mouse Age: 
Among  
hCD3+ cells 
Among hCD45+ cells Among hCD45+ cells 
NSG Mice 
Engraftment in Bone Marrow (16 weeks) 
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Intra-vaginal HIV infection 
 
Anti-retroviral combo 
therapy 
 
Evidence of latent HIV 
infection 
BLT-NSG Respond to Anti-Retroviral Therapy 
and Develop Latent HIV Pools 
Denton PW et al. 2012. J Virol  Jan;86(1):630-4. PMID:22013053 
40 
Other applications of 
humanized NSG 
include: 
 
Epstein Barr Virus, Ebola, 
Dengue, Malaria, 
Tuberculosis, and more… 
NSG Mice 
Cell Replacement Therapy for Type I Diabetes 
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NRG, NOD Rag1 gamma 
Mouse Nomenclature 
NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ 
(007799) 
Features 
NOD background contributes 
o Absence of hemolytic complement 
o Reduced dendritic cell function 
o Defective macrophages 
o Optimal human hematopoietic stem 
cell engraftment (Sirpa allele) 
Rag1 knockout: T and B cell 
deficiency 
o Radiation resistant 
Il2rg deficiency: NK cell 
deficient 
 
Pearson T et al. 2008. Clin Exp Immunol 154(2):270-84. PMID:18785974 
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Considerations: 
Emerging model 
Human Hematopoiesis in NRG Mice 
HSCs engraft efficiently in bone marrow and 
differentiate into 
o Myeloid lineage 
Erythroid precursors 
NK cells, monocytes, macrophages, dendritic cells 
o Lymphoid lineage 
T cells (CD4+ and CD8+) 
B cells 
Very high engraftment of PBMCs 
Pearson T et al. 2008. Clin Exp Immunol 154(2): 270-84. PMID:18785974 
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www.jax.org/jaxmice/cancer/xenoHosts 
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Pre-Engrafted Models Off The Shelf 
PDX and Humanized NSG Mice 
Enables economical  
proof-of-concept and  
pilot research studies with small cohorts 
Empower your research with greater accessibility to valuable 
resources  
Special Pricing now available for : 
o JAX Humanized-NSG Mice 
o JAX NSG Mice engrafted with Patient-derived Acute Myeloid 
Leukemia (AML) 
Thank you! 
 
Need help choosing the appropriate 
immunodeficient strain for your 
research?  
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